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Abstract
b-III spectrin is present in the brain and is known to be important in the function of the cerebellum. Heterozygous
mutations in SPTBN2, the gene encoding b-III spectrin, cause Spinocerebellar Ataxia Type 5 (SCA5), an adult-onset, slowly
progressive, autosomal-dominant pure cerebellar ataxia. SCA5 is sometimes known as ‘‘Lincoln ataxia,’’ because the largest
known family is descended from relatives of the United States President Abraham Lincoln. Using targeted capture and next-
generation sequencing, we identified a homozygous stop codon in SPTBN2 in a consanguineous family in which childhood
developmental ataxia co-segregates with cognitive impairment. The cognitive impairment could result from mutations in a
second gene, but further analysis using whole-genome sequencing combined with SNP array analysis did not reveal any
evidence of other mutations. We also examined a mouse knockout of b-III spectrin in which ataxia and progressive
degeneration of cerebellar Purkinje cells has been previously reported and found morphological abnormalities in neurons
from prefrontal cortex and deficits in object recognition tasks, consistent with the human cognitive phenotype. These data
provide the first evidence that b-III spectrin plays an important role in cortical brain development and cognition, in addition
to its function in the cerebellum; and we conclude that cognitive impairment is an integral part of this novel recessive ataxic
syndrome, Spectrin-associated Autosomal Recessive Cerebellar Ataxia type 1 (SPARCA1). In addition, the identification of
SPARCA1 and normal heterozygous carriers of the stop codon in SPTBN2 provides insights into the mechanism of molecular
dominance in SCA5 and demonstrates that the cell-specific repertoire of spectrin subunits underlies a novel group of
disorders, the neuronal spectrinopathies, which includes SCA5, SPARCA1, and a form of West syndrome.
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Introduction
Spectrins are a diverse family of membrane scaffold proteins.
They were originally found in erythrocytes where mutations result
in various haemolytic anemias [1,2]. Spectrins have been
identified in the brain [3] but until recently little was known of
the effects in humans of brain spectrin mutations. In 2006,
heterozygous mutations of the brain spectrin gene SPTBN2,
encoding b-III spectrin, were found to cause Spinocerebellar
Ataxia Type 5 (SCA5) [4]. SCA5 is an autosomal dominant,
slowly progressive, adult onset, pure cerebellar ataxia, which was
first identified in a large family who are the descendents of relatives
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of the US President Abraham Lincoln; SCA5 is therefore
sometimes referred to as ‘‘Lincoln ataxia’’ [5,6,7]. Two other
SCA5 families have been described in the literature, one from
France and one from Germany [8,9].
b-III spectrin is a 2,390 amino acid protein comprising an N
terminal domain containing the actin/ARP1 binding site, 17
spectrin repeats, (the latter containing regions which bind the
glutamate transporter EAAT4 [10], and ankyrin [11]), and a C
terminal domain of uncertain function. b-III spectrin forms
antiparallel tetrameric heterodimers with a-II spectrin, encoded
by SPTAN1. The tetrameric self-association probably requires the
presence of the C terminal b spectrin repeats, B16 and B17, and
the N terminal a spectrin repeats, A0 and A1, with absence of
these regions highly likely to impair the formation of a functional
tetramer [12]. Three heterozygous dominant mutations in
SPTBN2 have been reported to cause SCA5: in the US (Lincoln)
family a 13 amino acid in-frame deletion (E532_M544del) in the
third spectrin repeat, in the French family a small complex in-
frame deletion-insertion (L629_R634delinsW), also in the third
spectrin repeat, and in the German family a missense mutation
(L253P), in the N terminal domain. The mechanism of action of
these mutations is not immediately obvious and could be explained
by haploinsufficiency, in which the mutant allele is inactive and
the normal stoichiometry for tetramer formation is lost, a
dominant negative effect which suppresses wild type (wt) function,
or a gain of function effect. Several lines of evidence have
suggested that a dominant negative effect in SCA5 is most likely.
Using targeted gene disruption of mouse b-III spectrin, Perkins et
al, reported that homozygous knockout mice (b-III spectrin 2/2)
had cerebellar ataxia, a progressive loss of cerebellar Purkinje cells
and an associated decrease in the Purkinje cell specific glutamate
transporter EAAT4 [13]. The b-III spectrin 2/2 mutant mice
lack all full-length b-III spectrin but do express, at a low level, a
form of b-III spectrin (,250 KDa) that lacks most of the actin-
binding domain encoded by exons 2–6. The heterozygous mice (b-
III spectrin +/2) were reported to be normal. Further work has
shown that the L253P (German) missense mutation has a
dominant negative effect on wild type function by preventing
protein trafficking from the Golgi apparatus [14]. There is
evidence also that de novo in-frame mutations in SPTAN1 encoding
a-II spectrin have dominant negative effects, causing a form of
West Syndrome (infantile epilepsy with developmental delay) [15].
However, although experimental data has strongly suggested that
small in-frame mutations or missense mutations in a-II or b-III
spectrins have a dominant negative effect, no recessive mutations
in spectrins have been found, and such data would lend further
strong support for this hypothesis.
Here we report the first description of recessive mutations in
SPTBN2 in which there is a severe developmental childhood ataxia
but also significant cognitive impairment. The homozygous stop
codon c.1881C.A (p.C627X), was identified in three affected
individuals from a consanguineous family using targeted capture
and next generation sequencing and both the ataxia and cognitive
impairment co-segregate with the mutation. However, since more
than one mutation can co-segregate, particularly in consanguin-
eous families, we considered whether a second recessive mutation,
either homozygous or compound heterozygous, could account for
the cognitive impairment. We investigated this using a combina-
tion of SNP array analysis and whole genome sequencing, but
found no evidence of a second mutation.
We also investigated b-III spectrin 2/2 knockout mice [13] for
supportive evidence that the cognitive impairment in the human
subjects is caused by loss of b-III spectrin. We examined the mouse
model for morphological abnormalities of neurons in brain regions
(other than cerebellum), which are thought to be involved in
memory function including prefrontal cortical (PFC) layers, the
caudate putamen/striatum and hippocampus (HPC). Finally we
tested the mice using object recognition tasks, which have been
shown to correlate with function of the PFC and HPC [16,17].
The morphological and behavioural abnormalities found in the
knockout mice provide further evidence that the cognitive
impairment in our human subjects is an integral part of this novel
recessive disorder which we have called SPARCA1 (‘‘Spectrin-
associated Autosomal Recessive Cerebellar Ataxia type 1’’). We
suggest that this represents one of a novel group of disorders, the
neuronal spectrinopathies, which demonstrate that the cell-specific
functional repertoire of spectrin subunits are involved in brain
development including the cortex, in addition to cerebellar
development and function.
Results
Clinical phenotype and genetic analysis
The three affected individuals are from a UK family of Pakistani
origin with complex consanguinity (see Figure 1A), but no other
family history of neurological disorders. The clinical phenotype in
the 3 individuals is identical (Table 1). V1 was referred at the age
of 13 months with motor delay; she was extremely floppy and was
unable to crawl. She sat at 10 months, crawled at 18 months and
was pulling to stand at 20 months. She walked with a walker by the
age of 5 and started to walk with support at age 7. She was noted
to have language delay and at age 5 was just starting to join words
together. Global developmental delay was subsequently noted, she
was educated at a special school and now attends a college for
adults with special educational needs. On examination there are
abnormal eye movements with a convergent squint, hypometric
saccades, jerky pursuit movements, and an incomplete range of
movement particularly in the horizontal plane. There is obvious
dysmetria and dysdiadochokinesia of the limbs and gait ataxia with
inability to tandem walk without falling. Limb tone is normal,
reflexes are normal and plantars flexor and there is no evidence of
any sensory abnormality. Rombergs sign is normal. Neuropsy-
Author Summary
b-III spectrin is present in the brain and is known to be
important in the function of the cerebellum. Mutations in
b-III spectrin cause spinocerebellar ataxia type 5 (SCA5),
sometimes called Lincoln ataxia because it was first
described in the relatives of United States President
Abraham Lincoln. This is generally an adult-onset progres-
sive cerebellar disorder. Recessive mutations have not
previously been described in any of the brain spectrins. We
identified a homozygous mutation in SPTBN2, which
causes a more severe disorder than SCA5, with a
developmental cerebellar ataxia, which is present from
childhood; in addition there is marked cognitive impair-
ment. We call this novel condition SPARCA1 (Spectrin-
associated Autosomal Recessive Cerebellar Ataxia type 1).
This condition could be caused by two separate gene
mutations; but we show, using a combination of genome-
wide mapping, whole-genome sequencing, and detailed
behavioural and neuropathological analysis of a b-III
spectrin mouse knockout, that both the ataxia and
cognitive impairment are caused by the recessive muta-
tions in b-III spectrin. SPARCA1 is one of a family of
neuronal spectrinopathies and illustrates the importance
of spectrins in brain development and function.
Recessive Mutations in SPTBN2
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chological assessment reveals significant global cognitive impair-
ment with all IQ scales falling at the second percentile or below,
and with Full Scale IQ scores falling in the learning disabled range
(Table 1). A brain CT scan at age 2 did not show any abnormality,
but a recent MRI brain reveals significant cerebellar atrophy
(Figure 2A). V2 is the younger sibling of V1. She was noted to
have developmental delay in early childhood and also did not start
to walk until age 7. On examination, she has an identical clinical
phenotype to that of her sister except for occasional beats of
nystagmus on eye examination. She attends a school for children
with learning disabilities and a recent assessment (at age 16) shows
functioning in English and Mathematics at the level of an average
5–7 year old in the UK requiring special educational support.
Formal cognitive assessment also showed very similar impairments
to V1 with scores on all IQ scales falling at the second percentile or
below, and with Full Scale IQ scores falling in the learning
disabled range (Table 1). The difference between Verbal and
Performance IQ for each individual was not statistically significant
(p = 0.15). MRI imaging in V2 at age 6 revealed cerebellar atrophy
and this was found to have progressed over time (Figure 2Bi and
Bii). V3 is the first cousin of V1 and V2. He was noted to have
poor head control and balance in early childhood. Clinical
examination is identical to his cousins and also shows an identical
developmental profile in that he has just started to walk with
assistance at the age of 7. He also has an identical eye movement
disorder, a convergent squint, dysmetria and dysdiadochokinesia.
He is hypotonic with normal reflexes downgoing plantars and no
evidence of a sensory neuropathy. He attends a mainstream school
but requires full time one to one support. Cognitive assessment of
V3 also showed significant global cognitive impairment (Table 1).
The slightly higher IQ scores in V3 results from a floor effect in the
normative data rather than a significant difference in cognitive
ability from his older cousins. In this age cohort the lowest
attainable scores are VIQ=62, PIQ=73 and FSIQ=63 and
therefore V3 falls in the same learning disabled range as his
cousins. Brain imaging of V3 showed a normal cerebellum at age
5, but mild hypoplasia of the posterior corpus callosum (Figure 2C).
The normal appearance of the cerebellum in V3 at an early age is
not unexpected as both his cousins imaging shows progression with
time. Neurological examination of both sets of parents was entirely
normal, with no evidence of ataxia. The father of V1 and V2
works as a bus driver, having left school at age 16 with 5 GCSEs
(General Certificates of Secondary Education) and the father of
V3 works in a warehouse and has a similar educational
background. Formal psychometric testing in the father of V1
and V2 showed IQ indices falling in the low average range
consistent with his educational attainment. The father of V3 was
not available for testing but has very similar attainment levels to
his brother. Formal assessment of the mothers could not be
performed since neither speak English, but interview of the family
did not reveal any evidence of learning disability. There is no
history of the siblings or grandparents of the affected individuals
having any cognitive or neurological abnormalities.
We initially performed targeted capture of .100 known ataxia
genes (including SPTBN2) in a group of children with unexplained
ataxia including patient V3, followed by next generation
sequencing. In V3 we identified only one mutation, a homozygous
stop codon p. C627X (c.1881C.A), located in the third spectrin
repeat in SPTBN2 and used Sanger sequencing to confirm that all
three affected patients in the family had the same mutation
whereas the neurologically normal parents of V3, were shown to
be heterozygous for the mutation (Figure 1B). Since mutations in
b-III spectrin are associated with cerebellar degeneration in SCA5,
the newly identified mutation was considered likely to explain the
Figure 1. Genetic analysis of family with ataxia and cognitive impairment. A. Pedigree of family. B. Sanger sequencing of the mutation c.
1881C.A; p.C627X in normal, parents of V3 (IV3 and IV4) and affecteds, V1, V2, V3.
doi:10.1371/journal.pgen.1003074.g001
Recessive Mutations in SPTBN2
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ataxia, although of a developmental type with a much earlier
onset. However, since more than one mutation can co-segregate,
particularly in consanguineous families, we went on to consider the
contribution of the mutation in SPTBN2 to the observed cognitive
impairment. We therefore used SNP array analysis and whole
genome sequencing to search for any evidence of a second
mutation.
SNP array genotyping
To investigate whether a second homozygous mutation
segregated with the cognitive impairment, all 3 affected individuals
(V1, V2 and V3) and the unaffected parents of V3 (IV3 and IV4)
were genotyped to identify regions of homozygosity (ROH) shared
by V1, V2 and V3 and not present in either IV3 or IV4. This
analysis identified 20 shared homozygous segments on autosomes
totalling 17.1 Mb (Table 2). SPTBN2, on chromosome 11, was
located in the largest ROH shared by V1, V2 and V3 and not
present in either IV3 or IV4 (Figure 3).
Whole-genome sequencing
Whole genome sequencing of patient V2 was performed on the
Illumina HiSeq2000 as 100 bp paired end reads, using v3
clustering and sequencing chemistry. After duplicate reads
removal, the mean coverage across the genome was 25.66 with
90.4% of bases covered at 156or more. The mean coverage over
the 17.1 Mb ROH identified by SNP analysis was 25.96 with
93.4% of bases covered at 156 or more. Variant calling was
performed as detailed in the Materials and Methods.
We firstly based our data analysis on an autosomal recessive
disease model, caused by one or more rare homozygous mutations
and focused on homozygous variants occurring in the shared
ROH identified by SNP array analysis, filtering them out if they
were:
N present in 1000 Genomes with an allele frequency .1%
(http://www.1000genomes.org/)
N in a region of segmental duplication
Figure 2. Neuroimaging of patients. A. Sagittal T1w MRI in subject V1 age 21 demonstrating clear cerebellar atrophy. B. Sagittal T1w MRI in
subject V2 at age 6. Sagittal T1w MRI in subject V2 age 16 shows clear atrophy of the cerebellum. C. Sagittal T1w MRI in subject V3 showing
hypoplasia of posterior corpus callosum (white arrow).
doi:10.1371/journal.pgen.1003074.g002
Recessive Mutations in SPTBN2
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N observed as homozygous in other WGS500 samples within our
Institute (see Materials and Methods)
These filtering steps identified 68 candidate variants, subdivided
into functional classes (Table 3). Only 2 exonic variants were
found: a synonymous variant, NPHP1 L551L on chr2 which is not
predicted to be pathogenic and is not located near a splice site, and
the stop codon C627X in SPTBN2 on chr11 (Table 2 and Table 3).
Of the remaining variants, 21 were intergenic and also considered
unlikely to be disease related, and 4 variants were in untranslated
regions (59 UTR) or in non-coding RNAs and all were in positions
which scored poorly with PhyloP and GERP. In addition, none of
the associated genes (UBIAD1, LINC00116, LOC100130987)
appear to be relevant for this disorder. The other 41 were in
intronic and upstream regions but based on evolutionary
conservation and available information in databases (eg HGMD
[18]) we found no evidence of potential involvement in the disease.
The only likely pathogenic variant is the stop codon in SPTBN2.
We also considered a model of recessive inheritance with
compound heterozygous mutations segregating with the ataxia
and/or cognitive impairment. Our criteria were that all 3 affecteds
must have two different variants in the same gene and where this
occurred the variants should be in trans (ie each parent is a carrier).
We identified all potential compound heterozygous coding
variants present in the WGS data for individual V2. In total
there were variants fulfilling our criteria at 13 different loci but in
only 1 case were both variants present in all 3 affecteds and further
analysis revealed that in this instance both variants were also in the
father of V3 (ie were in cis). Furthermore, none of the variants
identified are known to be associated with ataxia or cognitive
impairment and the majority of genes had data suggesting an
alternative function (such as taste or fertility), nor were there any
likely candidates based on pathogenicity bioinformatic prediction
programs (Table S2).
Abnormal dendritic morphology of prefrontal cortical
neurons in b-III spectrin 2/2 mice
The phenotype of our patients suggested that b-III spectrin is
involved in cognitive development, in addition to being essential
for motor functions. We therefore utilised b-III spectrin knockout
mice which have progressive cerebellar degeneration and lack any
full length b-III spectrin [13], to further investigate the role of b-III
spectrin in other brain regions. Our previous work revealed that b-
III spectrin is required for the correct dendritic development of
Purkinje cells [19,20] and therefore we initially examined dendritic
organisation in other brain regions by immunostaining sagittal
sections from the brains of 6-week-old wild-type and b-III spectrin
knockout animals for microtubule associated protein 2 (MAP2), a
dendritic marker. This revealed irregular reactivity throughout the
PFC layers and within the caudate putamen/striatum of knockout
animals when compared to WT mice but no obvious difference in
the HPC (Figure 4A). However no difference was observed
between WT and b-III spectrin knockout animals when the cortex
and striatum were immunostained for tau or myelin basic protein
(MBP) indicating that there was no change to axonal structure
(Figure S1).
The PFC in humans is believed to be important for complex
cognitive tasks, and given there is evidence of a close association
between this area and the neocerebellum, as well as high
Table 2. Regions of homozygosity in V1, V2, and V3.
ROH ROH size (bp) Comments
chr1:11,008,695–11,512,411 503,716
chr1:152,466,882–152,773,905 307,023
chr2:110,432,886–111,586,214 1,153,328 Contains NPHP1 synonymous missense variant, L551L
chr4:1,755,491–2,268,126 512,635
chr5:42,431,016–42,911,014 479,998
chr6:42,231,419–43,196,182 964,763
chr7:73,889,810–75,160,045 1,270,235
chr8:92,965,409–93,493,424 528,015
chr11:44,874,510–51,372,036 6,497,526 Homozygous in IV4
chr11:55,091,268–59,054,448 3,963,180 Homozygous in IV4
chr11:66,108,660–68,097,826 1,989,166 Contains SPTBN2 stop codon, C627X
chr11:72,937,274–74,146,105 1,208,831
chr12:825,782–1,583,962 758,180
chr12:88,356,316–89,340,293 983,977
chr14:105,777,094–106,863,833 1,086,739
chr15:48,369,485–48,889,188 519,703
chr16:47,239,089–48,179,983 940,894
chr16:50,034,680–50,641,988 607,308
chr16:61,713,393–63,225,217 1,511,824
chr17:17,544,704–18,634,672 1,089,968 Homozygous in IV3
chr17:27,935,688–28,543,044 607,356
chr17:39,993,771–41,059,014 1,065,243
chr18:21,155,324–21,264,965 109,641
doi:10.1371/journal.pgen.1003074.t002
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expression levels of b-III spectrin in mouse [10] we further
investigated the prefrontal cortical region in b-III spectrin
knockout animals. There was no difference in the thickness of
individual prefrontal cortical layers (data not shown) but the
morphology of individual pyramidal neurons in b-III spectrin
knockout animals was found to be altered. Morphometric analysis
of dye-injected pyramidal neurons from layer 2/3 showed basal
dendrites in 8-week-old b-III spectrin knockout mice were
significantly thinner distally compared to wild type cells
(Figure 4B–4D). Moreover, the basal dendrites of knockout mice
tapered more rapidly than those of wild types, being significantly
reduced in thickness between 20 and 30 mm from the soma,
whereas wild type dendrites showed no significant narrowing until
90 mm from the soma. However, no difference in spine density was
observed between genotypes in either dye injected (Figure 4D:
+/+, 2.860.6, n = 8;2/2, 3.260.2 spine/mm3, n= 7; p = 0.56) or
Golgi-impregnated (Figure 4E: +/+, 12.461.7, n= 4; 2/2,
13.761.3 spine/10 mm, n= 6; p = 0.56) pyramidal neurons. Only
small sections of apical dendrites could be reconstructed from the
serial stacks of dye-injected cells. Nevertheless, quantification of
the short regions imaged, when normalized to length analysed,
indicated reduced apical dendritic volumes, and hence thinner
apical dendrites in b-III spectrin knockout animals (+/+,
4.360.47; 2/2, 2.560.36 mm3/mm, n= 6 for each genotype;
p = 0.011).
Corpus collosum appears normal in b-III spectrin 2/2
mice
Since patient V3 shows mild hypoplasia of the posterior corpus
callosum we examined this brain structure in 8-week old b-III
spectrin knockout animals to determine if the morphological defect
in the human subject could be a consequence of b-III spectrin loss
or is unlinked to the homozygous stop codon c.1881C.A
(p.C627X) mutation in SPTBN2. No signs of posterior hypoplasia
were observed in sagittal sections stained either with cresyl violet
Table 3. Number of candidate variants per functional class.
Functional Class Number of variants
Exonic Total 2
N Stop Gained 1
N Synonymous 1
59 UTR 1
ncRNA 3
Intronic 39
Upstream 2
Intergenic 21
doi:10.1371/journal.pgen.1003074.t003
Figure 3. SNP Zygosity data for chromosome 11 from affecteds V1, V2, V3, and V3’s parents IV3 and IV4. Red lines correspond to
homozygous SNPs and blue lines to heterozygous SNPs (the gap represents the centromere).
doi:10.1371/journal.pgen.1003074.g003
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(Figure 5A) or an anti-tau antibody (Figure 5B). Similarly width of
corpus callosum, measured from coronal sections immunostained
for MBP (Figure 5C), was no different between WT and knockout
animals (+/+, 469.7646.6; 2/2, 480.6641.3 mm, N=3 for each
genotype; p = 0.28).
b-III spectrin 2/2 mice are deficient in behaviour tasks
Four object recognition memory tasks (two- and four- novel
object preference, object-in-place and object location; Figure 6A–
6D) were carried out to assess whether b-III spectrin knockout
animals displayed any cognitive deficits. No impairment in the two
novel object recognition task (‘‘object identity’’) was observed in b-
III spectrin knockout animals compared with wild type animals
(Figure 6A); however knockout animals performed worse in the
four novel object recognition task (Figure 6B). Knockout animals
were also worse at discriminating between rearranged and non-
rearranged objects in the object-in-place task compared with litter
mate controls, shown by their failure to spend more time exploring
the two objects in different locations compared with the two
objects that had not moved (‘‘object displacement’’) (Figure 6C).
However, there was no significant difference in performance for
the object location task (Figure 6D). The poorer performance in
the four-novel object recognition task for knockout animals was
not a consequence of less exploration in the 5 minute sample
phase as in fact they explored more than wild type animals (+/+,
64.966.7; 2/2, 88.764.8 sec; p = 0.018). Similarly for the
object-in-place task although there was no significant difference
between genotypes there was a trend for greater exploration in
knockout animals (+/+, 4263.6; 2/2, 62.268.7 sec; p = 0.054).
Discussion
The integrated evidence from clinical, genetic and neuropsy-
chological analysis in humans and behavioural and morphological
analysis in a mouse model demonstrate that we have identified a
novel recessive disorder, SPARCA1, associated with mutations in
b-III spectrin. The 3 human subjects with a premature stop codon
Figure 4. Abnormal dendritic morphology in b-III spectrin 2/2 mouse compared to wild type. A. Sagittal sections immunostained for
MAP2 show irregular reactivity throughout prefrontal cortical layers and caudate putamen/striatum of 6-week-old b-III spectrin knockout (2/2) mice
compared to wild type (+/+) but normal staining within hippocampus (N= 3 each genotype; Bar, 20 mm). B. Top, Representative images of pyramidal
neurons in layer 2/3 prefrontal cortex from 8-week-old WT and b-III spectrin knockout mice filled with Alexa 568 (Bar, 20 mm). Bottom, Neuronal 3-D
reconstruction over laid using NeuronStudio software. C. Quantification of basal dendrite morphological parameters measured from reconstructed
images shows greater distal thinning of dendrites in cells from b-III spectrin knockout mice (open circles; N = 9) compared with WT cells (filled
squares; N = 8). All data are mean 6 SEM (* denotes significance between groups and # significance within a group.) D. High magnification image of
single basal dendrite showing distal thinning in b-III spectrin knockout compared to WT but presence of normal spines (Bar, 5 mm). E. High
magnification image of Golgi impregnated pyramidal neuron from prefrontal cortex of WT and b-III spectrin knockout mice (Bar, 10 mm).
doi:10.1371/journal.pgen.1003074.g004
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and the mouse knockout all have very early onset cerebellar ataxia,
indicating a developmental role for b-III spectrin. The human and
mouse knockout phenotype also show that b-III spectrin is
involved in cognitive development and function. The human
subjects have global cognitive impairment in the mild/moderate
range. The specific brain structures and connections associated
with this impairment are not yet known and further detailed
neuropsychological testing will be required. However, we have
shown that in the mouse knockout there are morphological
abnormalities especially thinning of dendrites in PFC neurons,
similar to that previously reported for Purkinje neurons [19], but
with no obvious changes in various regions of HPC (CA1, CA3
and dentate gyrus), and the behavioural tests in the mouse are
consistent with this. Based on published lesion studies, deficits in
the object-in-place task but not the object location task would
indicate defects in the PFC not HPC, since PFC is believed to
mediate memory for object location (O`object displacementO´),
whereas HPC integrates information as to object identity and the
temporal order of object presentation with HPC lesioned animals
being impaired on object location task [16,17,21]. However,
further to the above discussion, there is also increasing recognition
that the cerebellum itself has a direct role in cognition [22] and it is
possible that some of the phenotype results directly from cerebellar
abnormalities. Further investigation should also allow a detailed
analysis of which specific brain regions mediate mild/moderate
cognitive impairment in humans.
The data demonstrate that our b-III spectrin knockout mouse
[13] is an excellent model for the novel recessive disorder we have
identified and will allow further molecular analysis of b-III
spectrin, in addition to the morphological and behavioural
analysis. b-III spectrin is known to be expressed widely throughout
the brain, kidney, liver and testes and to be associated with the
Golgi and other cytoplasmic vesicles [23], but the mechanisms by
which mutations lead to impaired brain development are
unknown. The premature stop codon C627X identified in our
family is predicted to result in truncation of b-III spectrin near the
end of the 3rd spectrin repeat (Figure 7). This truncated protein
would be unable to form tetramers with a-II spectrin, nor be able
to bind to EAAT4 or ankyrin, but it is possible that there is
nonsense mediated decay and loss of the entire protein. Since
SPTBN2 is expressed at only very low levels in peripheral blood,
further in vitro expression studies will be required to determine this.
However, it is most likely that b-III spectrin is absent in the brain
of the human subjects and this has resulted in neuronal
dysfunction in widespread brain regions, notably cerebellum and
prefrontal cortex. Future studies will investigate other brain
regions such as striatum and perirhinal cortex as well.
Our findings also provide insights into the mechanism of
molecular dominance in SCA5: the heterozygous carrier parents
of the C627X stop codon in the SPARCA1 family are
neurologically normal despite carrying a stop codon which in
the homozygous state is a recessive loss of function mutation.
Therefore haploinsufficiency is highly unlikely to be the mecha-
nism underlying SCA5 and this lends considerable weight to the
body of experimental evidence suggesting that SCA5 results from
a dominant negative effect, possibly by interfering with normal
binding to ARP1 [13,14,24].
One difference between the human and mouse model is that the
mouse shows progressive motor deficits in addition to progressive
Purkinje cell loss whereas there is no evidence of clinical
progression in the patients at the moment despite one of our
subjects having progressive cerebellar atrophy on imaging. This
lack of clinical progression and discordance between the clinical
and imaging findings could suggest that there is significant
plasticity within the human cerebellum, although we cannot
exclude the possibility that slow clinical progression will occur with
time.
The phenotypic spectrum of neuronal spectrinopathies now
appears to be very wide. In SCA5, the ataxia is generally a pure
adult-onset ataxia whereas recessive mutations in SPTBN2 cause
SPARCA1, a more severe childhood ataxia with cognitive
impairment. In West Syndrome, associated with SPTAN1 muta-
tions, the patients have epilepsy, profound developmental delay
and in addition have shortening of the corpus callosum and
cerebellar vermis atrophy. Only one of our patients, V3, had
shortening of the corpus callosum and it is tempting to speculate
that this additional feature may be part of the SPARCA1
phenotype, although there are no signs of hypoplasia in the b-
III spectrin knockout mice. It also may be that this feature is
caused by another gene mutation or a genetic modifier and to
clarify this additional cases will need to be identified. Overall, our
data suggest that region specific expression of spectrin subunits is
important in prenatal brain development and further work is
required to define their temporal and spatial contribution.
Our data also suggest the possible and testable hypothesis that
the phenotype in neuronal spectrinopathies relates in part to the
total amount of functional spectrin tetramers: in SCA5, all a-II/b-
II tetramers are normal and functional but a-II/b-III tetramers
Figure 5. Absence of hypoplasia of posterior corpus callosum
in b-III spectrin knockout mice. Sagittal sections from 8-week old
WT (+/+) and knockout (2/2) animals stained with cresyl violet (A, Bar
200 mm) and anti-tau antibody (B, Bar 500 mm) with arrow pointing to
posterior corpus callosum. C. Coronal sections immunostained for MBP
(Bar 200 mm).
doi:10.1371/journal.pgen.1003074.g005
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will contain mutant b-III spectrin which likely have a dominant
negative action and may not be fully functional; in SPARCA1, a
recessive disorder, there is complete loss of the tetramerisation site
of b-III spectrin so there will be normal a-II/b-II tetramers but no
functional a-II/b-III tetramers, whereas the heterozygotes who
are effectively ‘‘haploinsufficient’’ have enough a-II/b-III tetramer
Figure 6. b-III spectrin knockout mice display deficits in some object recognition tasks. Diagram of task and performance of WT (+/+) and
b-III spectrin knockout mice (2/2) in the four object recognition tasks. Two-novel object recognition (A), four-novel object recognition (B), object-in-
place (C) and object location task (D). All data are mean 6 SEM (N= 6–9; * P,0.05).
doi:10.1371/journal.pgen.1003074.g006
Figure 7. Diagram of b-III spectrin/a-II spectrin tetramer. This is composed of 2 b-III spectrin and 2 a-II spectrin molecules and the location of
the homozygous stop codon C627X in SPTBN2 causing SPARCA1 relative to dominant mutations in SPTBN2 and SPTAN1. Mutations are only shown in
one of the two molecules. Loss or truncation of b-III is likely to prevent formation of normal tetramers. The glutamate transporter, EAAT4, binds near
the C terminus of b-III.
doi:10.1371/journal.pgen.1003074.g007
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to be clinically normal; in West Syndrome, caused by in-frame
dominant SPTAN1 mutations [15], the majority of both a-II/b-II
and a-II/b-III tetramers are abnormal resulting in the most severe
of the disorders to be described so far (Figure S2). This model
would suggest that homozygous loss of function a-II spectrin
mutations might be more severe or lethal and a very recent report
of an a-II knockout mouse supports this and it will be important to
identify the equivalent human disorder [25]. There may be other
disorders associated with human disease: dominant negative or
recessive mutations in b-II and proteins interacting with brain
spectrins may also have similar phenotypes. For example, a mouse
knockout model of Ankyrin G, was reported to cause Purkinje cell
degeneration [26] but a human phenotype has not yet been found.
In addition, seizures are described in SPTAN1 mutations [15] and
another b-III spectrin knockout [24] and it will be important to
search for spectrin mutations in epilepsy patients.
In conclusion, the identification of recessive mutations in b-III
spectrin provides evidence that the cell-specific repertoire of
spectrin subunits underlies a novel group of disorders, the
neuronal spectrinopathies, including SCA5, a dominant form of
West Syndrome and SPARCA1. It is likely that other human
disorders are caused by mutations in neuronal spectrins and
searches for these are in progress. We also demonstrate the power
of analysing complex phenotypes in consanguineous families by
using whole genome sequencing, which was critical in establishing
that both the ataxia and the cognitive impairment were caused by
the same mutation and illustrate how the use of genome
sequencing, even in single human families, can help provide
mechanistic insights into disease.
Materials and Methods
Ethics on study participants and animal analysis
Our institutional ethics committee approved the study on
human participants and specific consent was obtained to include
whole genome analysis. All procedures involving analysis of
mutant mice were carried out according to the United Kingdom
Animals (Scientific Procedures) Act (1986) and other Home Office
regulations under specific pathogen-free conditions.
Targeted resequencing and analysis
The exonic sequences of 129 genes known or suspected to be
associated with ataxia were selected for targeted capture (Table
S1) and 120-mer baits with 2X tiling designed using the Agilent
eArray design tool. The total size of the targeted region amounted
to 605.8 kb. Multiplex sequencing was performed on the Illumina
GAII with 51 bp paired-end reads. A total of 5,046,154 reads were
generated for patient V3 and aligned to the human reference
genome (GRCh37/hg19) with STAMPY [27] About 60% of the
reads mapped to the target region, providing a mean depth
coverage of 218.46with 89.8% of target bases covered at 306or
more. Single nucleotide variants (SNVs) and indels were called
respectively with SAMTOOLS [28] and DINDEL [29]. Variants
were annotated with respect to gene and transcripts using the
Ensembl database (release 62, Apr 2011 [30]) by means of the
associated Variant Effect Predictor tool.
Confirmation of variants using Sanger sequencing
Results were confirmed using Sanger Dideoxy Sequencing with
the following primers across exon 14 of SPTBN2: Forward:
CTACCTCTGCTGCACGACCT; Reverse: AGGGAGG-
GAAGTCCAAGAGA. Genomic DNA was amplified with Taq
Polymerase (Roche) and PCR products were used as templates for
sequencing with BigDye Terminator reagents (Life Technologies)
on a 3730xl DNA Sequencing Analyzer (Life Technologies). The
sequence traces were aligned to the gene-specific reference
sequence (NCBI build 37) with Sequencher 4.10.1 (Gene Codes).
SNP array genotyping and homozygosity mapping
Genotyping was performed using the Illumina HumanCy-
toSNP-12v1 BeadChip, containing nearly 300,000 genetic mark-
ers. Hybridization to the chip was performed according to
manufacturer’s protocols found on registration at http://www.
illumina.com/support/array/array_kits/humancyto-snp-12_v2-
1_dna_analysis_kit/documentation.ilmn. In brief, patient DNAwas
denatured, amplified and enzymatically fragmented and then
hybridized onto CytoSNP-12 BeadChips by rocking in an Illumina
hybridization oven at 48uC for 16–24 hrs. The BeadChips were
washed according to the Illumina Inc. protocol and the hybridized
DNA detected by primer extension with labelled nucleotides
followed by detection using fluorescent antibodies. The data were
processed using Illumina’s GenomeStudioV2009.2.
As SNP coordinates in the chip were reported with respect to
human genome build 36, we downloaded the corresponding
coordinates for build 37 from the website http://www.well.ox.ac.
uk/,wrayner/strand/, cross-checking them using the USCS
Genome Browser liftOver utility (http://genome.ucsc.edu/cgi-
bin/hgLiftOver) and the dbSNP database (Build 135 [31]). We
filtered out ,18,000 markers which could not be mapped
unambiguously to build 37 of the human genome. We further
excluded SNPS with missing calls in one or more samples, thus
reducing the number of markers to 271,208.
PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/
[32]) was used to identify regions of homozygosity (ROH) shared
by V1, V2 and V3 and not present in either IV3 or IV4. For V1,
V2 and V3, we applied relaxed parameters in order to include all
potential ROH, resulting in potential false positives but minimiz-
ing false negatives. We defined a homozygous region as a run of (at
least) 50 homozygous SNPS spanning more than 500 kb, allowing
for some heterozygous calls within it. Shared ROH were identified
from overlapping and allele matching segments. Further details of
the algorithm are provided on the PLINKwebsite. We used the
options: –homozyg –homozyg-group –homozyg-window-kb 500 –
homozyg-window-snp 50 –homozyg-snp 50 –homozyg-kb 500. All
other parameters were left at default values. ROH were then
identified in IV3 and IV4. In this case very stringent criteria were
applied to confidently include only true ROH and avoid false
positives. We defined a homozygous region as an uninterrupted
run of (at least) 500 homozygous SNP’s spanning more than 5 Mb.
In IV3 we identified 8 ROH on autosomes totalling 78 Mb (the
largest ROH was 18.4 Mb); in IV4 we identified 2 large ROH on
chromosome 11 present also in V1, V2 and V3 (Table 2 and
Figure 3). These regions were excluded in the search for
pathogenic variants as both IV3 and IV4 are unaffected. As a
result, the search was restricted to 20 regions totalling 17.1 Mb,
among which the ROH harbouring SPTBN2 was the largest.
Whole-genome sequencing
Data generation. Whole-genome sequencing of patient V2
was carried out as part of the WGS500 project, a collaboration
between the University of Oxford and Illumina to sequence 500
whole genomes of clinical relevance. (http://investor.illumina.com/
phoenix.zhtml?c=121127&p=irol-newsArticle&ID=1592299). At
time of writing 213 genomes have been completed and have been
grouped and organised in the WGS500 Data Freeze 3 (February
2012).
Library preparation and sequencing. Samples were quan-
tified using the High Sensitivity Qubit system (Invitrogen) and
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sample integrity was assessed using 1% E-Gel EX (Invitrogen).
2 ug* of DNA were fragmented using the Covaris S2 system.
Libraries were constructed using the NEBNext DNA Sample Prep
Master Mix Set 1 Kit (NEB) with minor modifications. Ligation of
adapters was performed using 6 ml of Illumina Adapters (Multi-
plexing Sample Preparation Oliogonucleotide Kit). Ligated
libraries were size selected using 2% E-Gel EX (Invitrogen) and
the distribution of fragments in the purified fraction was
determined using Tapestation 1DK system (Agilent/Lab901).
Each library was PCR enriched with 25 mM each of the following
custom primers:Multiplex PCR primer 1.0: 59- -39 Index primer:
59 CAAGCAGAAGACGGCATACGAGAT[INDEX]CAGT-
GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-39. In-
dexes were 8 bp long and part of an indexing system developed
in-house.
Four independent PCR reactions per sample were prepared
using 25% volume of the pre-PCR library each. After 8 cycles of
PCR (cycling conditions as per Illumina recommendations) the
four reactions were pooled and purified with AmpureXp beads.
The final size distribution was determined using a Tapestation
1DK system (Agilent/Lab901). The concentration of each library
was determined by Real-time PCR using the Agilent qPCR
Library Quantification Kit and a MX3005P instrument (Agilent).
Whole Genome Sequencing was performed on the Illumina
HiSeq2000 as 100 bp paired end reads, using v3 clustering and
sequencing chemistry. A PhiX control was spiked into the library.
We ran 2 lanes of the original library at 21.5 and 23 pM. Then, to
‘‘top up’’ to the required coverage, we ran the library in a
multiplex of 16 over 5 lanes at 18 and 18.5 pM
Data analysis. WGS reads were mapped to the human
reference genome (GRCh37d5/hg19) using STAMPY [27] and
duplicate reads removed using Picard (http://www.picard.
sourceforge.net/). After duplicate reads removal, the mean
coverage across the genome was 25.66 with 90.4% of bases
covered at 156 or more. The mean coverage over the 17.1 Mb
ROH identified by SNP analysis was 25.96with 93.4% of bases
covered at 156 or more. Coverage was calculated with custom
scripts and the BEDTOOLS package [33]. Identification of
variant sites and alleles was performed with Platypus (written by
Andrew Rimmer, Ian Mathieson, Gerton Lunter and Gil
McVean: http://www.well.ox.ac.uk/platypus), which can detect
SNPs and short (,50 bp) indels. Briefly, Platypus works by re-
aligning reads by putative haplotypes obtained from combining
candidate variants, and uses a statistical algorithm to identify the
haplotype(s) that best explain the read data, and infer variants and
their frequencies.
First, poorly or ambiguously mapped reads are filtered from the
data. Platpyus requires a minimum mapping quality of 20, which
equates to a nominal 1/100 chance of the read being incorrectly
mapped. Reads with large numbers of low quality base-calls (.20
bases with quality ,10) are also removed. This filtering helps to
remove spurious variant candidates caused by poor quality data or
reads mapped to difficult regions (e.g. long homopolymers or
tandem repeats).
Variant candidates are considered by Platypus if they are seen at
least twice in good quality reads. For SNPs, the variant base must
be seen at least twice with base-quality .=20. Indel candidates
are left-normalised, i.e. the inserted/deleted sequence is reported
in the left-most position possible.
Platypus then looks in ,100–200 base windows across the
genome, and creates haplotype candidates, based on the list of
variants in each window. Each haplotype may contain several
variants. A statistical algorithm is used to infer the frequency of
each haplotype in the data provided; this algorithm works by re-
aligning all the reads to each of the haplotypes, and uses
expectation-maximization to estimate haplotype frequencies, and
compute a likelihood for each haplotype. Platypus uses these
inferred frequencies and the likelihoods to compute a probability
for each variant candidate segregating in the data. These
probabilities are reported in the final output as a VCF file.
Finally the variants are filtered, to reduce the false-positive rate.
First, variants are only called if they have been assigned a
sufficiently high posterior probability (the threshold used by
Platypus is a phred score of 5). Additional filters are used to
remove variants called in low quality reads, or where the variant is
only seen on the forward or reverse strand.
We compared the data obtained by the SNP array for V2 with
the WGS of V2 and found that 99.85% of the calls were identical,
confirming the accuracy of the WGS.
WGS500 Data Freeze 3 (February 2012) includes 213
individual samples. The variant calling was performed as a two
step procedure. Initially, variants were called independently for
each individual WGS500 sample. The variants from all normal
(non-tumour) samples were then merged to generate a union set,
containing 26,952,978 unique entries. The second step involved
running Platypus on each sample using the variants in the union
set as candidates (i.e. as priors). For each variant, the number of
occurrences as heterozygous and homozygous in the union set was
recorded.
The variants were then processed with a functional annotation
pipeline based on the ANNOVAR software package (version of
October 2011 [34]). The following ANNOVAR databases (with
respect to human genome hg19) were used: RefSeq gene models;
dbSNP (Build 132); 1000 genomes allelic frequencies (November
2011); UCSC segment duplication scores; UCSC 46 species
conservation scores. Candidate variants were annotated with
predictions of functional importance from SIFT [35], PolyPhen2
[36], PhyloP [37] and GERP [38]. We screened known
associations to diseases with OMIM (http://www.omim.org/),
HGMD Professional (http://www.hgmd.org/) and GeneCards
(http://www.genecards.org/).
Neuropsychological assessments in family
Screening of cognitive function was undertaken using the
Wechsler Abbreviated Intelligence Scale (WASI).
Neuronal cell imaging
For immunostaining and histological analysis brains from wild
type and b-III spectrin knockout animals were removed and
immersion-fixed with either 1 or 4% paraformaldehyde in 0.1 M
sodium phosphate buffer, pH 7.4 overnight at 4uC and cryopro-
tected in 0.1 M sodium phosphate buffer (pH 7.4) containing 30%
sucrose. Tissue was embedded in OCT then 16 mm-thick sections
cut and mounted onto poly-L-lysine coated slides. Primary
antibodies used were mouse anti-MAP2 (Sigma), rabbit anti-tau
(DAKO) and rat anti-myelin basic protein (AbD Serotec).
Secondary antibodies were cyanine 3 (Cy3)-conjugated goat
anti-mouse IgG (Jackson laboratories), fluorescein isothiocyanate
(FITC)-conjugated goat anti-rabbit IgG (Cappel) and Alexa Fluor
488 –conjugated donkey anti-rat (Invitrogen). For Golgi impreg-
nation brains were removed and immersion-fixed with 4%
paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4
overnight at 4uC and processed as described previously [39]. For
cell filling animals were deeply anesthetized with isofluorane and
sacrificed by transcardial perfusion with 4% paraformaldehyde in
0.1 mM phosphate buffer, pH 7.4. Brains were dissected and
postfixed in 1% paraformaldehyde overnight at 4uC. Coronal
sections were cut (250 mm-thick) and individual neurons in layer
Recessive Mutations in SPTBN2
PLOS Genetics | www.plosgenetics.org 12 December 2012 | Volume 8 | Issue 12 | e1003074
2/3 of the prefrontal cortex were visualized with a 206 immersion
objective and injected with 0.2 mM Lucifer Yellow (Sigma) and
0.02 mM Alexa FluorAR 568 hydrazide (Invitrogen). Slices were
post-fixed and 4% paraformaldehyde overnight at 4uC and wet-
mounted with Vectashield onto 0.13 mm thick borosilicate glass
and neurons imaged using the Alexa 568 dye. All images were
captured using a Zeiss inverted LSM510 confocal scanning laser
microscope and serial stacks used for three-dimensional recon-
struction of dendritic arbors using NeuronStudio software (CNIC).
Behaviour tasks in mice
Animals were handled for 1 week and then habituated to the
arena (40 cm640 cm640 cm) for 5 d before testing. All tests
involved a 5 min sample phase followed by a 5 min test phase after
a delay of 5 min. Exploratory behaviour was recorded via a
WebCam positioned above the testing arena and two researchers
blind to genotype scored the investigation of each sample using
ANY-maze software (Stoelting). As described previously [16,21]
for the novel object preference tasks one object from the sample
phase was replaced with a novel object in the test phase; the
object-in-place task comprised switching the location of two
familiar objects in the test phase; and for the object location task
position of one familiar object was changed (Figure 6A–6D).
Duplicate copies of familiar objects were used in the test phases to
remove any chance of olfactory cues being present. Discrimination
ratios were calculated as the time spent exploring the novel or
location switched object(s) divided by the total time spent
exploring all objects.
Statistical analysis of mouse studies
Statistical analysis was performed using Student’s t-test, two
sample assuming unequal variance, apart from analysis of filled
pyramidal cells where a two-way ANOVA was used.
Supporting Information
Figure S1 Normal axonal immunostaining in b-III spectrin
knockout mice. A. Coronal and sagittal cortical sections from 8-
week old WT (+/+) and b-III spectrin knockout mice (2/2)
immunostained for tau (Bar, 20 mm). B. Coronal sections of cortex
and striatum (low and high magnification) stained for MBP (Bar,
20 mm).
(TIF)
Figure S2 Possible disease mechanism of impaired spectin
tetramer formation. a-II shown in yellow, b-II in dark blue, b-
III in light blue. Normal tetramers are shown in Black and the
mutant dominant tetramers in red bold text and mutant recessive
(loss of function) tetramers in red italic text. In the normal there
are 4 possible comibinations of either a-II/b-II or a-II/b-III. In
the SPARCA1 heterozygous carriers tetramers containing b-II are
all normal, but L of the tetramers containing b-III are either
absent (if nonsense mediated decay is present) or truncated. These
patients are clinically normal illustrating that the tetramers with
mutant b-III do not have a dominant effect nor is there
haploinsufficiency. In SCA5 the same total number of spectrin
tetramers are present as in the heterozygous carriers of the
SPARCA1 mutation, but they are clinically affected and the
mutation therefore must have a dominant negative effect, rather
than be caused by haploinsufficiency. In SPARCA1 all a-II/b-III
are non-functional, and in West syndrome, both a-II/b-II and a-
II/b-III tetramers are affected resulting in a more severe
phenotype.
(TIF)
Table S1 Ataxia genes screened by targeted next generation
sequencing. The panel included 117 genes known to cause ataxia
in humans, in animal models or were considered likely candidates
based on function.
(DOC)
Table S2 Compound Heterozygous variants identified in V2.
Compound heterozygous variants identified in V2 filtered as
detailed in Material and Methods. a =Wellcome Trust Centre for
Human Genetics Whole Genome Sequence data, Freeze 3.
b =Exome Variant Server. c = SIFT Probability of being patho-
genic; 0 = highest; 1 = lowest. d = Polyphen2 Probability of being
pathogenic: 0 = lowest; 1 = highest. e = PhyloP, measures conser-
vation at individual columns of nucleotides. f = PhastCons, is a
hidden Markov model-based method that estimates the probability
that each nucleotide belongs to a conserved element. g =GERP,
Genomic Evolutionary Rate Profiling (GERP) (35 species
alignment) conservation score.
(DOC)
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